# Endogamy and high prevalence of deleterious mutations in India: evidence from strong founder events

- 3 Pratheusa Machha<sup>1,2</sup>, Amirtha Gopalan<sup>3,4</sup>, Yamini Elangovan<sup>5</sup>, Sarath Chandra Mouli Veeravalli<sup>3</sup>,
- 4 Divya Tej Sowpati<sup>1,2</sup>, Kumarasamy Thangaraj<sup>1,2\*</sup>
- 6 <sup>1</sup>CSIR-Centre for Cellular and Molecular Biology, Hyderabad, Telangana 500007, India
- 7 <sup>2</sup>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
- 8 <sup>3</sup>Department of Rheumatology and Clinical Immunology, Krishna Institute of Medical Sciences,
- 9 Secunderabad, Telangana 500003, India
- <sup>4</sup>Present address : Department of Rheumatology and Clinical Immunology, Nizam's Institute of
- 11 Medical Sciences, Hyderabad, Telangana 500082, India
- <sup>5</sup>Department of Biotechnology, Bharathidasan University, Tiruchirapalli, Tamil Nadu 620024,
  India
- 14
- 15 \*Correspondence to
- 16 K. Thangaraj
- 17 CSIR-Centre for Cellular and Molecular Biology
- 18 Uppal Road, Hyderabad
- 19 India 500007
- 20 Email: <u>thangs@ccmb.res.in</u>
- 21 Tel: +91-40-27192634
- 22

# 23 Abstract

Founder events influence recessive diseases in highly endogamous populations. Several Indian 24 25 populations have experienced significant founder events and maintained strict endogamy. Genomic studies in Indian populations often lack in addressing clinical implications of these 26 27 phenomena. We performed whole-exome sequencing of 281 individuals from four South Indian groups to evaluate population-specific disease causing mutations associated with founder events. 28 29 Our study revealed a high inbreeding rate of 59% across the groups. We identified ~29.2% of the 30 variants to be exclusive to a single population and uncovered 1,284 novel exonic variants, 31 underscoring the genetic underrepresentation of Indian populations. Among these, 23 predicted 32 as deleterious were found in heterozygous state, suggesting they may be pathogenic in a 33 homozygous state and are common in the endogamous groups. Approximately 40-68% of the identified pathogenic variants showed significantly higher occurrence rates. Pharmacogenomic 34 35 analysis revealed distinct allele frequencies in CYP450 and non-CYP450 gene variants, 36 highlighting heterogeneous drug responses and associated risks. We report a high prevalence of 37 ankylosing spondylitis in Reddys, linked to HLA-B\*27:04 allele and strong founder effect. Our 38 findings emphasize the need for expanded genomic research in understudied Indian populations 39 to elucidate disease risk and medical profiles, eventually aiming towards precision medicine and 40 mitigating disease burden.

41

### 42 Keywords

43 Founder event, Endogamy, Novel variants, Runs of Homozygosity, Pharmacogenomics

44

- 45 46
- 47
- 48

49

### 50 Introduction

51 India is a land of extraordinary human diversity in terms of cultural, social and religious 52 practices, with over four thousand anthropologically well-defined population groups, who speak more than 300 different languages. Majority of the Indian populations practice strict endogamy, 53 resulting in substantial barriers to gene flow. Consanguinity, i.e. union between close relatives is 54 highly pervasive in Southern India<sup>1</sup>. The rich genetic diversity within these largely endogamous 55 56 groups, underscores the need to increase the Indian ethnic representation in genetic data, crucial 57 for advancing global precision medicine. Unfortunately, there exists a significant disparity in the 58 inclusion of the non-European population in genomic studies. Capturing the genetic diversity of 59 these underrepresented communities can address the existing disparities improving disease risk 60 predictions, origin and early detection, diagnosis, clinical care, and precision medicine.

Founder events and population bottlenecks also shape the genetic constitution of Indian populations. Founder events occur when a new population is established by a small group of individuals separating from the ancestral population. This leads to reduced genetic diversity and distinctive allele frequency patterns, often resulting in a higher prevalence of rare recessive diseases<sup>2</sup>. Due to founder events, deleterious variations persist, more so when compounded by inbreeding practices. Such populations are valuable for examining how evolutionary processes influence disease genetics and evolution.

The small fraction of genetic variants that are not shared among populations, may also define 68 69 their distinct metabolic phenotypes. Pharmacogenomics, which studies the impact of genetic 70 makeup on drug response, is a promising avenue for personalized medicine. There are notable 71 inter- and intra-ethnic differences in genetic variants associated with drug absorption, distribution, metabolism, and elimination (ADME)<sup>3</sup>. For example, inconsistent responses to 5-72 73 Fluorouracil among South Asian ethnic populations are attributable to DPYD gene variations<sup>4</sup>. However, most pharmacogenomic studies focus on European subjects, leading to a Eurocentric 74 75 bias in drug dosing recommendations. Although limited studies exist profiling gene-drug 76 interactions within India's inter- and intra-ethnic diversity, the vast cultural diversity necessitates multiple frameworks. 77

78 In our previous study<sup>5</sup>, we identified 81 unique South Asian groups that exhibit stronger founder 79 events than the Finns and Ashkenazi Jews, both known for a high incidence of recessive diseases 80 linked to founder events. The strength of these founder events was quantified by analyzing the 81 distribution of identity-by-descent (IBD) segments, which are stretches of genomic regions shared between individuals inherited from a common ancestor. While occasional reports mention 82 83 specific rare diseases in select groups, comprehensive studies exploring the genetic composition and the potential for harboring deleterious variations predisposing these populations to certain 84 diseases are lacking. In our present study, we performed an extensive interrogation of 281 high 85 86 coverage whole exome sequences obtained from individuals belonging to four anthropologically 87 distinct populations of India, each with a high IBD score, to (i) assess their levels of inbreeding (ii) identify the novel/population-specific and pathogenic variants (iii) estimate the distribution 88 89 of pathogenic variants that might render populations-specific disorders and (iv) evaluate the genomic variants that affect drug metabolism in these groups. Further, in our findings, we reveal 90 91 a widespread presence of Ankylosing Spondylitis (AS) in one of our study populations. We 92 believe our study is one of the few that thoroughly explores the genetic landscape of Indian 93 populations. This work marks an important step toward understanding Indian genetic diversity 94 and has significant implications for the development of personalized medicine and public health 95 strategies.

#### 96 Results

#### 97 Study populations and sequencing

98 Whole exome sequencing data was generated for all the collected samples from the four selected 99 populations (Kalingas, Kallars, Reddys and Yadavs) of southern India, reported to have strong founder events<sup>5</sup>. We generated a final call set comprising of a total of 281 individual sequences 100 101 across the four groups, inferred to be unrelated to the second degree. The analysis of the whole-102 exome data across the four populations demonstrated high-performance sequencing, achieving 103 an average aligned read depth of approximately 99X in the target regions. The dataset was 104 filtered using various parameters, including minimum read depth, proportion of missing data, and Phred quality scores, resulting in a high-confidence set of 140,921 variants across the four 105 106 groups.

### 107 Inbreeding coefficient reveals high endogamy

Inbreeding and consanguinity is a common practice in several ethnic groups in South Asia<sup>6</sup>. To 108 109 understand the nature of inbreeding in our populations, we estimated the inbreeding coefficients for each individual and also the genealogical relationship between parents. Across populations, 110 111 around 59% of the individuals had a positive inbreeding coefficient (56.1% in Kalinga, 87.5% in Kallar, 56% in Reddy and 38.4% in Yadays). Mating type inference as depicted in Figure 1 112 showed that the Yadavs had comparatively more outbred individuals (61.6%), whereas the other 113 three populations had a lower proportion of individuals whose parents are unrelated - 43.8%, 114 115 12.5% and 44% for Kalinga, Kallar and Reddy, respectively (Table 1). We found no individuals exhibiting avuncular relationships between their parents. 116

#### 117 Runs of homozygosity

Founder events, endogamy and consanguinity contribute to higher homozygosity in populations, 118 119 with characteristic differences in length and number of homozygous tracts. Their sizes and 120 numbers are informative; with the shorter ones reflecting autozygosity (IBD) and longer 121 segments being suggestive of recent inbreeding events. We used runs of homozygosity (ROHs), 122 *i.e.*, contiguous genomic regions with identical maternal and paternal copies to elucidate the 123 nature of inbreeding in the population groups. For our study, ROHs were grouped into five 124 distinct classes - class A (1 - 2Mb), class B (2 - 4Mb), class C (4 - 8Mb), class D (8-16Mb) and class E (> 16 Mb) as depicted in Figure 2a (Supplementary Table 1). We detected ROHs in all 50 125 126 individuals from the Reddy group, 70 out of 73 from the Kalinga group, 71 out of 72 from the Kallar group, and 65 out of 86 from the Yadav group. Considering homozygous tracts exceeding 127 128 1.0 Mb in length revealed a wide range of values in the individuals, varying between a minimum 129 of just 1 ROH tract to a maximum of 46 tracts through the genome. The ROH statistics across 130 the groups are given in Table 2. The most extreme case was an individual from the Kalinga group, who had approximately 250.5 Mb of homozygous regions (Fig. 2b), covering about 7.8% 131 132 of the autosomal genome, as can be seen in Figure 2c.

133 Next, we attempted to see if the prevalence of ROH segments of a particular class correlates with 134 the age of founder events. In all four groups, individuals exhibited larger proportions of 135 homozygous tracts falling in class B and C (Fig. 2a). The occurrence of class C ROH segments

136 indicates a shared ancestor approximately 12 generations ago. This observation partially coincides with the established timing of founder events documented for the groups in previous 137 138 study<sup>7</sup>, wherein, the authors report the founder event to have taken place around 9 - 11 gBP (generations Before Present) in Kallars, 6 - 15 gBP in the Reddys and 4 - 7 gBP in the Yadav 139 group. The Kalinga group was not a part of their study. While using a threshold of 20cM, we 140 141 observed a major fraction (> 50%) of the homozygosity in each individual arising from the 142 smaller segments, i.e < 8 cM. Also, the proportion of the autosomal genome occupied by the cumulative length of the smaller ROH tracts in the range of 1 - 8 Mb (class A - C) was higher 143 than that occupied by longer tracts > 8.0 Mb (class D & E) for almost all the individuals in all 144 four population groups, providing additional affirmation on the occurrence of founder events in 145 these groups (Fig. 2c). The analysis also revealed that ~ 38% of the samples display at least one 146 ROH segment exceeding 8Mb. The equally higher prevalence of longer segments (> 8.0 Mb) 147 aligns with the existing practice of endogamy and of consanguineous unions in the populations 148 of South India. Both the founder events and inbreeding are observed to play a pivotal role in 149 shaping the homozygosity in these groups. 150

#### 151 Inter-population comparison

152 Principal Component Analysis (PCA) was performed by combining genetic data of the 281 individuals with 1000 Genome phase 3 dataset (1kG phase3). As expected, we observed that the 153 154 groups aligned closely to the South Asian samples (Supplementary Fig. 1). In inter-population 155 comparison, we found that around  $\sim 29.2\%$  of the total variants across all the four groups were found in just a single individual or population (population-specific), while 39.7% variants were 156 shared by all the four populations (Fig. 3). At most, only 6.7% of variants are shared among 157 158 three populations (Kalinga, Kallar, and Yadav), and 6.6% are shared between two populations (Kallar and Yadav). This highlights the distinct genetic constitution of the four populations. 159

# 160 Novel variants

Post-filtering for each population separately, we detected a total of 73,599 high quality variants in Kalinga, 80,384 in Kallar, 79,255 in Reddy and 82,761 in Yadav (Supplementary Fig. 2a) in the exome data. Comparing these variants with nine widely used and publicly available population datasets (see methods), we segregated known and novel variants in each population

(Supplementary Table 2). We identified 1,284 novel genetic variants, encompassing variants in 165 the coding, UTR and splice regions, across the four groups. Population-wise, in Reddys, 526 166 novel variants (0.66% of the total variant set) were identified, while Kalingas had 472 exonic 167 168 variants (0.64%) to be novel. Kallars presented 205 novel variants, constituting 0.26% of the total, followed by Yadavs with just 86 of them, accounting for 0.1% of the total (Supplementary 169 170 Fig. 2b, Supplementary Fig. 3). Importantly, a comparison among different population groups revealed that the identified novel variants are exclusive to their respective group, with only a 171 maximum of 4 novel variants being shared between the Yadav and the Kalinga groups, while 172 173 only one novel variant is common among the Kalinga and the Reddys. Further, the asymmetrical distribution of these novel variants can be characterized as an enrichment of rare and missense 174 175 variants, as the majority of the novel variants having a MAF (Minor Allele Frequency) between 176 2-5 and the number decreasing with increase in the MAF (Supplementary Table 2).

177 Given that we observe an excess of rare novel variants at functional sites in our populations, we 178 consider the effect of these variants on fitness and selection using different approaches. After 179 annotation with Annovar and Ensembl VEP against different databases, these variants were 180 analyzed for their potential consequences (see methods). We detected a limited number of 181 potentially deleterious novel variants - 7 in Kalingas, 4 in Kallars, 9 in Reddy and 3 in the Yadavs. These are either non-synonymous variants or are present in the splice sites. An 182 183 important aspect to mark here is that none of the individuals display homozygosity for the novel 184 potentially deleterious genetic variants (Table 3). We then predicted the impact of these variants on the stability of the protein. Of the 17 genes with missense variants, 15 of them displayed a 185 186 destabilizing/unfavorable effect on the protein, while two of them in the ACOT8 and the MAP4K1 genes had a stabilizing/favorable effect. 187

#### 188 Known variants and enrichment analysis

For the known variants that were annotated as pathogenic/likely pathogenic in ClinVar and thereby, referred to as "known deleterious" variants were majorly frameshift indels, stopgain or non-synonymous variants (Supplementary Fig. 4). We annotated 21 variants to be deleterious in Kallars, 30 each in the Kalingas and Reddys and 19 in the Yadavs (Supplementary Table 3). In comparison with the reported allele frequencies in the 1kG\_phase3 dataset, a high proportion of these variants exhibited significantly (padj<0.05) higher AF, ranging between ~33% in Kallars

and Kalingas to ~42% in Yadavs. Similar trends were also observed on comparisons with the 195 196 GenomeAsia100k dataset (GAs100k) as depicted in Figure 4a. An inter-group comparison gave 197 us six genes that are hosting pathogenic/likely pathogenic variants with a significant MAF in two 198 or more groups (Supplementary Fig. 5). Similarly for the "known potentially deleterious" (predicted) variants, notable proportions were observed to be significantly (padj<0.05) enriched 199 200 in the populations : ranging from approximately 39% in Yadavs to 47% in the Reddys, and around 65% in the Yadav and Kallar groups to 66% in the other two, on comparison with the 201 202 AFs reported in the 1kG\_phase3 and GAs100k datasets, respectively (Fig. 4b).

An over-representation analysis was performed to ascertain whether the high occurrence of founder variants in each group are enriched in specific pathways, molecular-functions, or cellular-components beyond what would be anticipated by random chance. The significant enriched terms (FDR<0.05) resulting from the Gene Ontology resource analysis in CPDB primarily included hydrolase activity, superoxide dismutase activity, t-UTP complex cellular component, along with others (Supplementary Table 4).

#### 209 Pharmacogenomic diversity

210 To delve into the pharmacogenomic profile of the study populations, we considered the pharmacogenetically important alleles listed in Tier1 of the Clinical Pharmacogenetics 211 212 Implementation Consortium (CPIC) drug-gene pairs, along with the Pharmacogenomics 213 KnowledgeBase (PharmGKB). The analysis was further classified into three different categories 214 of genes - cytochrome-P450 (CYP450) genes, non-CYP450 genes and the Human Leukocyte 215 Antigen (HLA) genes. We genotyped the first two groups of genes with the PyPGx<sup>8</sup> tool. Herein, 216 we observed substantial diversity within the CYP450 genes (Fig. 5a, 5b) - CYP2B6, CYP2C19, 217 *CYP2C9* and *CYP2D6*. A carrier frequency exceeding 1% for several of the Tier1 218 pharmacovariants within these genes was observed across all the four groups (Table 4, Supplementary Table 5). However, for a majority of them, the AFs remain comparable to those 219 220 documented for the South Asians, available on the CPIC website (Supplementary Table 6). For 221 instance, *CYP2C9\*3* had similar high allele frequencies as reported in the Indian populations<sup>9</sup>. The notable deviations were the *CYP2C19\*3* having an AF of 11.11% and 15.34% in Kallars 222 223 and Yadavs (compared to 2.73% in SAS), CYP2D6\*3 exhibited an AF of 13.7% in Kalingas and 224 20.45% in Yadavs (1.01% reported in SAS); and CYP2D6\*4 that showed an AF of 23.29% and

225 20.83% in Kalingas and Kallars, respectively (8.89% in SAS). Kallars had a representation of 226 ~6% UM along with ~26% RM and ~15% PM individuals for the CYP2C19 gene that is 227 involved in the metabolism of several xenobiotics, including some proton pump inhibitors and 228 antiepileptic drugs. An occurrence of *CYP3A5\*3* (A6986G) allele at an AF of ~0.4, similar to the reported AF allele frequency outlined for South Indians<sup>10</sup> was observed in the Kalingas. The 229 230 variant has been assigned "No function" by CPIC for drugs like tacrolimus, eventually resulting 231 in inter-individual differences - PM at ~34%, IM at ~51% and NM at ~15%. The other three groups consist of samples with only NM and IM phenotypes. 232

233 Secondly, for the non-CYP450 genes (Fig. 5c, 5d), we observed a high number of PM 234 individuals for the drug atazanavir in only Kalingas. A total of 12 individuals (~17%) who are 235 homozygous for UGT1A1\*80+\*28 are possibly at an increased risk for developing atazanavirrelated hyperbilirubinemia<sup>11</sup>. We see a significant proportion of individuals with rs149056 236 variant in SLCO1B1 gene, associated with statin-induced myopathy due to decreased efficacy in 237 238 uptake of statins (mostly simvastatin and atorvastatin), in all groups, except the Reddys. For the 239 identified Tier1 variants in our study groups, the majority exhibited an AF akin to those recorded for the South Asians. However, notable exceptions include rs2231142 in the ABCG2 gene, 240 associated with rosuvastatin pharmacokinetics<sup>12</sup> demonstrating a significantly higher AF 241 242 (FDR<0.05) in the Kalingas; rs3918290 and rs2297595 associated with DPYD deficiency-linked 243 fluorouracil toxicity<sup>13</sup> was found to be significantly enriched (FDR<0.05) in the Reddy and the Yadav groups, respectively. Additionally, rs2108622 (V433M) causing reduced CYP42 activity 244 and leading to the requirement of increased warfarin dosage<sup>14</sup> displayed significance (FDR<0.05) 245 246 in the Yadav group.

247 Thirdly, among the highly polymorphic HLA genes, we noted that Kallar, Kalinga and Yadav groups exhibited greater diversity in the HLA-B gene as compared to the HLA-A gene, while 248 249 Reddys showed nearly similar proportion of allelic diversity for both the genes (as depicted in 250 Supplementary Fig. 6). In general, we noted a considerable prevalence of approximately 31% of 251 our study subjects carrying a HLA-B genotype associated with life-threatening drug toxicities including allopurinol-induced (*HLA-B*\*58:01)<sup>15</sup> or carbamazepine-induced (*HLA-B*\*15:02) 252 Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)<sup>16</sup> and fatal hypersensitivity 253 254 reactions to abacavir (*HLA-B\*57:01*) in people with HIV infections<sup>17</sup>.

## 255 Ankylosing Spondylitis (AS) in the Reddy population

256 We note a marked prevalence of the HLA-B\*27:04 genotype, accounting for 13% allele 257 frequency within the Reddy samples. *HLA-B27*, a member of the major histocompatibility class I (MHC), is well established for its association with Ankylosing Spondylitis (AS) and in India, 258 AS cases typically exhibit HLA-B27 positivity in the range of 80 - 90%<sup>18</sup>. Through clinical 259 collaboration with the Krishna Institute of Medical Sciences (KIMS), Hyderabad, Telangana, we 260 261 successfully identified a significant proportion (54%, 7 out of 13 heterozygotes) of the genotype carriers testing positive for AS. We also observed that around ~4.72% of diagnosed AS cases in 262 263 the hospital records belong to the Reddy community, with a notable concentration of patients coming from the area of our sample collection and the adjacent villages. Furthermore, among the 264 265 seven AS-positives from our dataset, two individuals have parents classifying as unrelated to each other, suggesting that besides consanguineous unions, founder events can also play a 266 267 substantial role in certain diseases in Indian populations.

268 AS, a polygenic disorder, is one of the most common forms of inflammatory arthritis, 269 predominantly affecting the axial skeleton and sometimes involving various other organs like the 270 eyes, gastrointestinal tract; significantly diminishing the quality of life for those affected. Hence, 271 we investigate the role of the second most common gene, ERAP1 (Endoplasmic Reticulum 272 Aminopeptidase 1), known to be associated with AS, in our sample set. We identified variants in 273 the *ERAP1* gene and attempted to delineate the haplotypes in the AS-positive samples, focusing 274 on eight widely studied variant sites. Alongside the wild type, we observed the prevalence of 275 four different haplotypes - EPIMKDRE, EPIVKNQE, EPMMKDRE and ERIMKDRE (Table 5).

#### 276 Methods

#### 277 Study subjects and data generation

Objective of this study was to discern the genetic variants with potential implications in clinical phenotypes and diseases in populations with strong founder events. We selected four populations, which were reported to have high IBD scores and also have a huge census size of above or nearly 1 million individuals<sup>5</sup>. For the study, we collected samples of 101 individuals from the Kalinga population of Andhra Pradesh, 92 from the Kallars of Tamil Nadu, 66 from the Reddy group of Andhra Pradesh, and 94 from the Yadavs of Pondicherry (now Puducherry). To

the best of our knowledge, all participants were in good health. Blood samples were collected from the volunteers and DNA was isolated using the phenol-chloroform method<sup>19</sup>. Whole exome sequencing libraries were prepared using the TruSeq Exome library preparation kit and sequencing was performed on the Illumina Novaseq 6000. The paired-end sequencing was done to target a vertical coverage of 100X.

To have a whole genome representation for our study on clinically relevant variants, we genotyped a subset of 96 individuals (24 from each population group) for 700,604 variant sites on Infinium Global Screening Array-Multi Disease (GSA-MD v3.0) array. From each of the population, 24 random unrelated samples were selected and processed for GSA. This array was chosen for its relevant and curated clinical research markers from ClinVar and multi-ethnic exonic content from ExAC database or other published GWAS studies.

#### 295 Variant calling, filtering and quality metrics

Following basic quality control checks, adapter trimming was performed using Cutadapt v2.8. Alignment of the sequencing data to the human reference genome (build GRCh38) was performed using DRAGEN v3.9.3 to generate individual GVCF (genomic variant call format) files followed by joint genotyping to generate a single multi-sample VCF (variant call format) file for each population groups. An additional step of Variant recalibration was carried out using Genome Analysis Toolkit (GATK v4.4.0.0) by standard quality filters. We achieved a mean coverage of ~99X on target regions for all the samples (Supplementary Table 8).

To exclude subjects with second degree relatedness, the kinship estimates were called using 303 PLINK 2.0 - `KING` and removed one sample from each pair having a kinship value > 0.0884. 304 305 Further, low quality samples with less than 50X coverage and more than 50% missingness were removed. Post filtering of the samples, we have a final call set consisting of a total of 281 306 307 individual sequences (Kalinga-73, Kallar-72, Reddy-50 and Yadav-86) healthy individuals, inferred to be unrelated to the second degree. Stringent variant filtering strategies were applied 308 309 for each of the groups separately to produce a high quality dataset. We used VCF tools v0.1.16 to exclude variants that were (i) non-biallelic (ii) genotyped in less than 95% of the samples (iii) 310 311 Genotype Quality (GQ) less than 30 (iv) minimum read depth (minDP) less than 8 (v) presented a Hardy Weinberg test value  $p < 10^{-6}$  and (vi) Minor Allele Frequency (MAF) less than 0.02. 312

Post filtering, to assess the probability of false positives, the transition-transversion (ts/ty) and 313 the concordance rate with dbSNP was estimated. The values are in accordance with the expected 314 315 for exome studies. Further, to validate that the selected groups are non-overlapping, we 316 computed the Weir and Cockerham  $F_{st}$  estimates between the groups (Supplementary Table 8). We considered pairs with weighted  $F_{st} < 0.004$  to be overlapping<sup>5</sup>. However, we do not find any 317 318 overlap between the groups suggesting that they do not intermarry. Analyzing the exome data for each population separately, we detected a total of 73,599 high quality variants in Kalinga, 80,384 319 in Kallar, 79,255 in Reddy and 82,761 in Yadav (Supplementary Fig. 1a). 320

For the GSA dataset, we conducted sample filtering to eliminate samples with a missingness exceeding 2% and those with any sex ambiguity. However, this step did not result in any sample loss. In the subsequent variant quality filtering steps, we removed duplicate variant sites and variants with less than 95% genotype rate across all samples. The genotyping rate for the final GSA dataset was ~0.99 (Supplementary Table 7).

# 326 Variant annotation

327 The post-QC exome dataset as well as the GSA data for each population was annotated both by

328 Ensembl Variant Effect Predictor (VEP v102) and Annovar.

# 329 Inbreeding and mapping regions of homozygosity

To detect the inbred individuals and infer the parental mating type, we used the FSuite v.1.0.4 pipeline<sup>20</sup>. It involves a method of estimating the individual inbreeding coefficients, obtained as F-median. We used the filtered exome files to generate 100 (default) random submaps. The proportions of the outbred and inbred - first cousins, second cousins and double-first cousins were calculated for each group.

The ROH segments were called from the exome dataset pruned for LD using PLINK; sliding window = 50kb, step size = 5 Single Nucleotide Polymorphisms (SNPs) and  $r^2$  threshold = 0.5. The homozygous regions were called for each sample with PLINK v1.9, the parameters optimized for WES<sup>21</sup>. This involves a sliding window of 50kb without any heterozygous sites, while keeping the rest of plink parameters at default (plink options : --homozyg-snp 50,-homozyg-window-het 0). Only ROH with a length of 1Mb were selected. The ROH segments

were binned into five-length classes : 1-2Mb, 2-4Mb, 4-8Mb, 8-16Mb and >16Mb, identified as 341 class A-E, respectively. Each ROH length class represents the estimated number of generations 342 from a common ancestor, calculated as  $E(L_{IBD-H|gcA}) = \frac{100}{2 acA}$ , where  $E(L_{IBD-H|gcA})$  is the length of 343 the ROH segment and gcA stands for the number of generations from the common ancestor<sup>22</sup>. 344 345 Based on the assumption that 1cM equals 1Mb, we could estimate that the ROH classes from class A to class E, date back to approximately 50, 20, 12.5, 6 and 3 generations ago. The number 346 347 of ROH segments, total length of these segments and the mean ROH length for each individual class was calculated. 348

# 349 Population variant analysis

The final filtered variant call set for each of the population groups was categorized into rare (MAF 2-5), common (MAF 5-25) and very common (MAF >25) (Supplementary Table 2). Due to small sample size for the groups, we had filtered out the variants with MAF < 2 to achieve a high-confidence variant set.

354 To identify novel variants, we compared the identified and filtered variants from each group against nine known datasets namely - 1kG\_phase3<sup>23</sup>, GAs100k<sup>24</sup>, gnomAD exome dataset, 355 dbSNP151, the draft human pangenome<sup>25</sup>, ClinVar v.20221231, TopMed freeze 8 356 (https://bravo.sph.umich.edu/freeze8/hg38/downloads), and two Indian-specific datasets - one of 357 the Andamanese<sup>26</sup> and the second a collection of 836 refined Indian clinical research exome 358 359 dataset<sup>27</sup>. To check if a variant is shared in a database, we matched the chromosome, position and 360 both the REF and ALT alleles. The shared variants are referred to as the Known variants and the 361 rest are called the Private variants with respect to the dataset of comparison. Finally, we made a 362 final collection of variants that are totally unique to the populations in study and call them the Novel variants. 363

#### 364 Characterization and functional enrichment of the known and novel variants

Novel potentially deleterious variants - We put two different criteria to classify any variant to be putatively deleterious. One, from the VEP annotated vcf files, we filtered for the variants that were deemed to be of High Impact by VEP (such as frameshift, splice-site, stop-gain) and High Confidence (HC) by the Loss of Function (LoF) plugin. Two, we looked separately for *in silico* 

predictions by SIFT<sup>28</sup>, PolyPhen2<sup>29</sup>, and CADD v1.6<sup>30</sup>. Any variant annotated by the first two to be "deleterious" and "probably\_damaging", respectively; and having a CADD score above 30 (i.e the variant lies in the top 0.1 of deleterious variants in the human genome) were taken into consideration. Finally, the variants that pass either of our two criteria were classified to be potentially deleterious , in this case Novel potentially deleterious variants.

Known deleterious variants - These are the known variants for each population group that areannotated as "pathogenic/likely pathogenic" by ClinVar in the Annovar annotated files.

Known potentially deleterious variants - The known variants underwent a similar filtering
strategy as for the novel potentially deleterious variants. Additionally under our second criterion,
along with SIFT, PolyPhen and CADD, the known genomic variants were also annotated by two
other *in silico* tools and those confirmed to be "deleterious" by LRT <sup>31</sup> and "disease causing" by
MutationTaster<sup>32</sup>; were considered to be potentially deleterious.

For the known deleterious and potentially deleterious variants, the AF (allele frequency) was compared against 1kG\_phase3 and GAs100k datasets for significance by performing Fisher's exact test followed by Benjamini-Hochberg correction for FDR (False Discovery Rate) to account for multiple testing. The ones with p.adj < 0.05 are considered to be significant.</p>

385 An over-representation analysis for the biological pathways of the genes mapped by the known 386 deleterious/potentially deleterious variants was performed in the ConsensusPathDB program (http://cpdb.molgen.mpg.de/). As sensitivity analysis, we are calling a known variant to be a 387 388 founder variant only if present in a significantly higher allele frequency (padj < 0.05) in the population (both compared to 1kG\_phase3 and GAs100k dataset). The genes with significant 389 390 known/potentially deleterious variants were given as input to the ConsensusPathDB (CPDB) program. The selected genes were the target and the complete list of genes present in the exome 391 392 target sites was uploaded as reference, while selecting the GO pathway option. We incorporated a significance criteria of FDR < 0.05 in selecting the GO terms. 393

#### 394 Effect of novel potentially deleterious variants on protein stability

Following the *in silico* prediction of novel variants, we proceeded to assess the potential impact of these predicted novel deleterious variants on protein stability. This was done with the help of

I-Mutant 2.0<sup>33</sup>, a Support Vector Machine (SVM) based tool that predicts the impact of single point mutations on the protein stability, given the protein structure or sequence. For each missense novel deleterious variant, we determined whether it exhibited a destabilizing effect (negative  $\Delta\Delta G$ ) or a stabilizing effect (positive  $\Delta\Delta G$ ) on the protein under standard conditions of pH 7 and room temperature. Here,  $\Delta\Delta G$  is the predicted free energy difference and expressed as:  $\Delta\Delta G = \Delta Gmutant - \Delta Gwild-type$ .

#### 403 **Pharmacogenetics and ERAP1 haplotype estimation**

404 Pharmacogenomic variants associated with specific gene-drug responses were mined from the PharmGKB database at https://www.pharmgkb.org/ with clinical annotation of level 1A or 1B, 405 406 since these are the variants demonstrating the highest evidence for actionable clinical implications of gene-drug associations. Allelic and the gene phenotype interpretations for the star 407 allele genes (both cyt P450 and non-cyt P450 genes) was done using PyPGx v0.20.0<sup>8</sup> tool. Using 408 the genomic data, the PyPGx tool predicts the PGx genotypes and phenotypes, namely Normal 409 410 Metabolizer (NM), Intermediate Metabolizer (IM), Poor Metabolizer (PM), Rapid Metabolizer (RM) and Ultrarapid Metabolizer (UM). For the HLA-A and HLA-B genes, xHLA v.1.2<sup>34</sup> tool 411 412 was used which utilizes the aligned bam files as input. Further, we computed the allele frequencies for the actionable genetic variants and their corresponding phenotypes by analyzing 413 414 the output from the above two tools.

To compute the protein haplotypes of *ERAP1* gene, we constructed the haplotypes as a combination of eight amino acids at the coding SNP positions - rs3734016 (E56K), rs26653 (R127P), rs26618 (I276M), rs2287987 (M349V), rs30187 (K528R), rs10050860 (D575N), rs17482078 (R725Q) and rs27044 (Q730E), the haplotype represented in the same order as the sites mentioned here. These sites were selected as they are the most commonly reported variant sites in the gene and are also the ones mostly studied in connection with AS.

# 421 Discussion

Founder events and population bottlenecks significantly influence genetic diversity and disease
risk profiles in contemporary populations. These events cause allelic frequency shifts that have
resulted in prominent genetic discoveries, notably in the Ashkenazi, Finnish, Amish, Icelandic

and others. Endogamy/consanguinity contribute to increased homozygosity beyond what random mating would predict. Higher incidences of recessive disorders are typically found in founder as well as endogamous communities. In our previous study on South Asian populations<sup>5</sup>, we identified 81 out of 263 South Asian groups that experienced founder events stronger than the archetypal Finnish and Ashkenazi Jewish populations. India is characterized by diverse populations practicing strict endogamy. However, comprehensive studies on the disease risks and pharmacogenomic profiles of the Indian populations are scant.

432 Our current study reports high levels of endogamy in four Indian populations previously 433 identified as having strong founder events. We depict a high percentage of ~59% of the total individuals to be inbred across the four groups, and present both recent and ancestral parental 434 435 relatedness as compelling evidence to the prevailing levels of genome wide homozygosity in the subjects. Individuals born from closely related parents often carry genetic burden, with several 436 437 stretches of DNA inherited from a common ancestor. These sequences characterized by continuous homozygous sites, ROHs, increase the likelihood of expressing deleterious 438 439 mutations<sup>35</sup>. At the population level, inbreeding decreases genetic variability, with the length of ROH regions reflecting the number of generations since the inbreeding event. Our findings show 440 441 high frequencies of both short and long ROH tracts, indicating a combination of founder events 442 and high endogamy rates in the groups. These insights have significant implications for assessing 443 the long-term effects of inbreeding on human health and utilizing ROHs to identify loci susceptible to recessive disorders. 444

We identified clinically significant genetic variants in both known and novel sets across the four populations. Notably, we found a large number of novel exonic variants (1,284) with a minor allele frequency (MAF) > 2%, highlighting the genetic diversity and distinctiveness of Indian populations. These novel variants are unique to their respective populations, likely a result of strict endogamy practices. Twenty three of these novel variants have been annotated through *in silico* analysis as potentially deleterious, impacting protein stability. Their absence in homozygous form suggests that they may be pathogenic recessive variants.

Given the occurrence of founder events, we anticipated a high load of deleterious variants and an increased risk of recessive diseases, similar to observations in Finns and Ashkenazi Jews. We identified several pathogenic/likely pathogenic variants and predicted many potentially

pathogenic/loss-of-function (pLoF) exonic variants across the four populations. Most samples 455 were heterozygous for known pathogenic mutations, particularly for rare monogenic disorders, 456 such as mutations in the VWF gene causing autosomal recessive Von Willebrand disease. For 457 some genes, we found that the presence of paralogs allows for greater tolerance to loss-of-458 function variants<sup>36</sup>, while others are linked to disorders with variable penetrance or are 459 influenced by additional regulatory and external factors, such as NQO1 gene variants<sup>37</sup>, which 460 are key in breast cancer progression. Additionally, several variants showed significant deviations 461 462 from their typical occurrence rates in South Asian populations.

463 Apart from the genetic disease risk, understanding diversity in the genetic variants impacting an individual's response to medications holds crucial clinical implications. There is a global 464 465 emphasis to increase pharmacogenetic testing to ensure drug safety and increase drug effectiveness. Recent pharmacogenomic research has brought into light marked inter-population 466 disparities in drug metabolism, therapeutic efficacy and safety profiles, highlighting a pressing 467 concern<sup>38</sup>. In our work, we sought to investigate in our study groups, the variability in the 468 469 prevalence of the VIP pharmacogenomic variants. We reported the presence of 470 *UGT1A1\*80+\*28*, known for its association with Gilbert syndrome, and *CYP3A5\*3* genetic 471 polymorphisms only in the Kalingas. CYP3A5\*3/\*3 results in CYP3A5 non-expressor, exhibiting poor clearance of the drug tacrolimus which is used to prevent post-transplantation 472 organ rejection<sup>39</sup>. While the allelic frequency for CYP3A5\*3 in Kalingas stands similar to 473 474 literature reported values for the south Asian populations, it is crucial to emphasize here that this uniformity does not universally apply, considering the absence of the allele in the other three 475 groups. We observed a likewise scenario wherein the reported CYP2C19\*3 (a premature stop 476 477 codon in exon 4) levels in both Kallars and Yadavs differs considerably from the stated frequency of 0.08 among South Indians<sup>40</sup>. Other pharmacovariant of importance is the rs2231142 478 479 (421C>A) in the ABCG2 gene, which decreases the ATPase activity of ABCG2, increasing 480 rosuvastatin accumulation in the systemic circulation, a drug used for the management of 481 dyslipidemia and coronary heart disease. Second is the rs2108622 in the CYP4F2 gene linked to 482 altered vitamin K<sub>1</sub> metabolism, wherein the rs2108622-T carriers require a higher warfarin dose. Furthermore, we also document the presence of rs3918290 and rs2297595 variants in the DPYD 483 484 gene, related to severe toxicities in cancer patients treated with fluoropyrimidines like fluorouracil. 485

Our study highlights a significant prevalence of Ankylosing Spondylitis (AS) within the Reddy 486 population, primarily linked to the HLA-B27:04 risk allele. AS is a highly familial disease, with 487 488 *HLA-B27* contributing to 20.1% of its heritability<sup>41</sup>. While data from the Indian subcontinent is limited, HLA-B27:04 and HLA-B\*27:05 subtypes have been noted as highly prevalent in AS 489 490 cases in South India<sup>42,43</sup>. To investigate this further, we collaborated with hospitals and found that 491 the KIMs hospital in Hyderabad reported approximately ~140 patients to be Reddys from a total of 2,963 AS-positive cases. Notably, 28.6% (40 in 140) of these Reddy AS cases were from a 492 particular geographical region, which includes our sample collection area and nearby regions. 493 Further, *ERAP1*, the second most important gene known to be definitely associated with AS, is 494 495 highly polymorphic and is known to exhibit genetic diversity across different ethnicities. However, the association between *ERAP1* and AS is thought to be attributable to combinations 496 of haplotypes, affecting *ERAP1* function<sup>44</sup>. We discovered four distinct haplotypes not previously 497 reported, despite our small sample size. These patients exhibited typical AS symptoms such as 498 peripheral joint and lower back pain, stooped posture, and skin rashes. Studies on ERAP1 499 500 haplotypes highlight the gene's role and its interaction with HLA genes in disease, though the 501 prevalence and functional distinctions of specific haplotypes remain debated. The presence of HLA-B27, combined with a family history of AS, significantly increases the risk of developing 502 the disease<sup>45</sup>, raising serious clinical concerns for the Reddy population due to the high incidence 503 504 rate.

505 In yet another similar example of population-specific disorder, we would like to highlight the 506 high incidence of Epidermolysis Bullosa in Kallar group from an adjacent district to our area of 507 sample collection (unpublished work). However, we do not observe such phenotype in our Kallar 508 samples. Both these examples underscore the prevalence of endogamy in India not only at the 509 population level, but also at the sub-population level, within small geographical regions. Disease 510 associated variants can gain prominence in a founder population with successive generations, 511 more so compounded by inbreeding.

512 Our study highlights the importance of understanding the clinical and pharmacogenomic impacts 513 of founder events and endogamy in the Indian populations. Population-specific disparities in the 514 field are of high relevance in the context of large-scale genetic inquiries and for nuanced disease 515 risk assessments. Our findings underscore the need for further research to validate and extend

these insights. We advocate for creating an accessible database categorizing genetic variations by ethnic background, facilitating precise genome scans for disease risk and drug-response-related polymorphisms. This approach aims to enable tailored treatment strategies, ensuring personalized medications based on unique genetic profiles. This could further help in development of health policies that establish guidelines for specific risk groups. This would mark a pivotal step towards eliminating pathogenic variants and reducing the occurrence of diseases in vulnerable populations.

523

# 524 Data availability

525 The raw sequence data for the samples included in this study has been submitted under the526 BioProject ID PRJNA1112977 (to be released on manuscript publication).

#### 527 Funding

PM was supported by the DBT JRF-SRF research fellowship. KT was supported by J C Bose
Fellowship from Science and Engineering Research Board (SERB), Department of Science and

530 Technology (JCB/2019/000027).

# 531 **Competing interests**

532 The authors declare no competing interests for this work.

### 533 Authors contributions

PM - study design, conceptualization, methodology, sample collection, data generation, data analysis and curation, validation, visualization, writing - original draft, review and editing; AG sample collection, clinical data curation; YE - sample collection, SCM - supervision of clinical data curation and validation; DTS - supervision, resources and visualization; KT - supervision, study design, conceptualization, validation, writing - review and editing, funding acquisition, project administration, resources and visualization.

# 540 Ethics approval

541 The project was carried out in accordance with the guidelines set by the Institutional Ethical

542 Committees of the Centre for Cellular and Molecular Biology, Hyderabad, India.

# 543 **Consent to participate**

544 Informed written consent was obtained from all the participating volunteers included in the 545 study.

# 546 Acknowledgements

547 We extend our gratitude to all the participants involved in this study. Our sincere thanks to 548 Akshay Kumar Avvaru and Deepak Kumar Kashyap for critically reviewing the manuscript and 549 for informative discussions. We are grateful to Tulasi Nagabandi from CCMB NGS facility for 550 library preparation and sequencing. We are thankful to Payel Mukherjee for demultiplexing the 551 NGS data.

552

# 553 References

- Mastana, S. S. Unity in diversity: an overview of the genomic anthropology of India. *Ann Hum Biol* 41, 287–299 (2014).
- Ruiz-Perez, V. L. *et al.* Mutations in a new gene in Ellis-van Creveld syndrome and Weyers
   acrodental dysostosis. *Nat Genet* 24, 283–286 (2000).
- 558 3. Evans, W. E. & Johnson, J. A. Pharmacogenomics: The Inherited Basis for Interindividual
  559 Differences in Drug Response. *Annual Review of Genomics and Human Genetics* 2, 9–39
  560 (2001).
- 4. Hariprakash, J. M. *et al.* Pharmacogenetic landscape of DPYD variants in south Asian
  populations by integration of genome-scale data. *Pharmacogenomics* **19**, 227–241 (2018).
- 563 5. Nakatsuka, N. *et al.* The promise of discovering population-specific disease-associated genes
  564 in South Asia. *Nature genetics* 49, 1403–1407 (2017).
- 565 6. Mastana, S. S. Unity in diversity: an overview of the genomic anthropology of India. *Ann*566 *Hum Biol* 41, 287–299 (2014).

567 7. Tournebize, R., Chu, G. & Moorjani, P. Reconstructing the history of founder events using
568 genome-wide patterns of allele sharing across individuals. *PLOS Genetics* 18, e1010243
569 (2022).

570 8. Lee, S. 'Steven'. README. (2023).

- 571 9. Nizamuddin, S. et al. CYP2C9 Variations and Their Pharmacogenetic Implications Among
- 572 Diverse South Asian Populations. *Pharmacogenomics and Personalized Medicine* **14**, 135– 573 147 (2021).
- 574 10. Krishnakumar, D. *et al.* Genetic polymorphisms of drug-metabolizing phase I enzymes
  575 CYP2E1, CYP2A6 and CYP3A5 in South Indian population. *Fundam Clin Pharmacol* 26,
  576 295–306 (2012).
- 577 11. Kane, M. Atazanavir Therapy and UGT1A1 Genotype. in *Medical Genetics Summaries* (eds.
  578 Pratt, V. M. et al.) (National Center for Biotechnology Information (US), Bethesda (MD),
  579 2012).
- 580 12. Song, Y., Lim, H.-H., Yee, J., Yoon, H.-Y. & Gwak, H.-S. The Association between ABCG2
  581 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic
  582 Review and Meta-Analysis. *Pharmaceutics* 14, 501 (2022).
- 583 13. Toffoli, G. *et al.* Clinical validity of a DPYD-based pharmacogenetic test to predict severe
  584 toxicity to fluoropyrimidines. *Int J Cancer* 137, 2971–2980 (2015).
- 585 14. Singh, O., Sandanaraj, E., Subramanian, K., Lee, L. H. & Chowbay, B. Influence of CYP4F2
  586 rs2108622 (V433M) on warfarin dose requirement in Asian patients. *Drug Metab*587 *Pharmacokinet* 26, 130–136 (2011).
- Tassaneeyakul, W. *et al.* Strong association between HLA-B\*5801 and allopurinol-induced
  Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. *Pharmacogenet Genomics* 19, 704–709 (2009).
- 16. Leckband, S. G. *et al.* Clinical Pharmacogenetics Implementation Consortium guidelines for
  HLA-B genotype and carbamazepine dosing. *Clin Pharmacol Ther* **94**, 324–328 (2013).
- 593 17. Mallal, S. et al. Association between presence of HLA-B\*5701, HLA-DR7, and HLA-DQ3
- and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *The Lancet* 359, 727–
  732 (2002).
- 18. Malaviya, A. N. Spondyloarthritis in India. *Indian Journal of Rheumatology* **15**, S2 (2020).
- 597 19. Thangaraj, K. et al. CAG Repeat Expansion in the Androgen Receptor Gene Is Not

- Associated With Male Infertility in Indian Populations. *Journal of Andrology* 23, 815–818(2002).
- 600 20. Gazal, S., Sahbatou, M., Babron, M.-C., Génin, E. & Leutenegger, A.-L. FSuite: exploiting
  601 inbreeding in dense SNP chip and exome data. *Bioinformatics* **30**, 1940–1941 (2014).
- 21. Nutile, T. *et al.* Whole-exome sequencing in the isolated populations of Cilento from South
  Italy. *Scientific Reports* 9, 4059 (2019).
- 604 22. Curik, I., Ferenčaković, M. & Sölkner, J. Inbreeding and runs of homozygosity: A possible
  605 solution to an old problem. *Livestock Science* 166, 26–34 (2014).
- 606 23. A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
- 607 24. Wall, J. D. *et al.* The GenomeAsia 100K Project enables genetic discoveries across Asia.
  608 *Nature* 576, 106–111 (2019).
- 609 25. Liao, W.-W. *et al*. A draft human pangenome reference. *Nature* **617**, 312–324 (2023).
- 610 26. Mondal, M. *et al.* Genomic analysis of Andamanese provides insights into ancient human
  611 migration into Asia and adaptation. *Nature Genetics* 48, 1066–1070 (2016).
- 612 27. Kausthubham, N. *et al.* A data set of variants derived from 1455 clinical and research
  613 exomes is efficient in variant prioritization for early-onset monogenic disorders in Indians.
  614 *Human mutation* 42, e15–e61 (2021).
- 28. Ng, P. C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. *Nucleic Acids Res* 31, 3812–3814 (2003).
- 617 29. Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting Functional Effect of Human
  618 Missense Mutations Using PolyPhen-2. *Curr Protoc Hum Genet* **0** 7, Unit7.20 (2013).
- 30. Rentzsch, P., Schubach, M., Shendure, J. & Kircher, M. CADD-Splice—improving genomewide variant effect prediction using deep learning-derived splice scores. *Genome Medicine*13, 31 (2021).
- 622 31. Chun, S. & Fay, J. C. Identification of deleterious mutations within three human genomes.
  623 *Genome Res* 19, 1553–1561 (2009).
- 32. Schwarz, J. M., Rödelsperger, C., Schuelke, M. & Seelow, D. MutationTaster evaluates
  disease-causing potential of sequence alterations. *Nat Methods* 7, 575–576 (2010).
- 33. Capriotti, E., Fariselli, P. & Casadio, R. I-Mutant2.0: predicting stability changes upon
  mutation from the protein sequence or structure. *Nucleic Acids Res* 33, W306–W310 (2005).
- 628 34. Xie, C. et al. Fast and accurate HLA typing from short-read next-generation sequence data

- 629 with xHLA. Proceedings of the National Academy of Sciences **114**, 8059–8064 (2017).
- 35. Gao, Z., Waggoner, D., Stephens, M., Ober, C. & Przeworski, M. An Estimate of the
  Average Number of Recessive Lethal Mutations Carried by Humans. *Genetics* 199, 1243–
  1254 (2015).
- 36. Hsiao, T.-L. & Vitkup, D. Role of duplicate genes in robustness against deleterious human
  mutations. *PLoS genetics* 4, e1000014 (2008).
- 37. Moscovitz, O. *et al.* A mutually inhibitory feedback loop between the 20S proteasome and
  its regulator, NQO1. *Molecular cell* 47, 76–86 (2012).
- 38. Ortega, V. E. & Meyers, D. A. Pharmacogenetics: implications of race and ethnicity on
  defining genetic profiles for personalized medicine. *Journal of allergy and clinical immunology* 133, 16–26 (2014).
- 39. Lamba, J., Hebert, J. M., Schuetz, E. G., Klein, T. E. & Altman, R. B. PharmGKB summary:
  very important pharmacogene information for CYP3A5. *Pharmacogenet Genomics* 22, 555–
- 642558 (2012).
- 40. Jose, R. *et al.* CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south
  Indian population. *Fundamental & Clinical Pharmacology* **19**, 101–105 (2005).
- 41. Cortes, A. *et al.* Identification of multiple risk variants for ankylosing spondylitis through
  high-density genotyping of immune-related loci. *Nat Genet* 45, 730–738 (2013).
- 42. Haridas, V. *et al.* Human leukocyte Antigen-B\* 27 allele subtype prevalence and disease
  association of ankylosing spondylitis among south indian population. *Indian Journal of Rheumatology* 13, 38–43 (2018).
- 43. Kumar, S. *et al.* Prevalence of HLA-B\*27 subtypes in the Tamil population of India with
  Ankylosing spondylitis and its correlation with clinical features. *Hum Immunol* 82, 404–408
  (2021).
- 44. Reeves, E., Colebatch-Bourn, A., Elliott, T., Edwards, C. J. & James, E. Functionally distinct
  ERAP1 allotype combinations distinguish individuals with Ankylosing Spondylitis. *Proceedings of the National Academy of Sciences* 111, 17594–17599 (2014).
- 45. Brown, M. A. *et al.* Susceptibility to ankylosing spondylitis in twins the role of genes, HLA,
  and the environment. *Arthritis & Rheumatism* 40, 1823–1828 (1997).
- 658
- 659



662 663

Individual sample

Fig. 1: Proportion of inbred individuals across groups. The mating type inference for each
individual was done. The gray lines indicate the inbreeding coefficient values for first cousins
(1C), second cousins (2C) and double-first cousins (2x1C). A high level of inbreeding (~59%)
was detected across the four populations.



#### 668 669

670 Fig. 2: a) ROH segments across the populations. ROH regions spanning greater than 1Mb genomic region are considered to be significant and were distributed into five classes based on 671 the length– class A (1-2Mb), class B (2-4Mb), class C (4-8Mb), class D (8-16Mb) and class E 672 (>16Mb). b) Relationship between the number and the sum of ROH segments per 673 individual across the four population groups. c) Proportion of genome covered by ROH 674 675 regions below 8Mb (1-8Mb) and above 8Mb. A high proportion of genome occupied by ROHs in both categories indicates the presence of both founder events and recent inbreeding in the 676 677 groups.



679

Fig. 3: Upset plot showing the distribution of community-specific variants, and variants 680 681 **shared among the groups.** Variants were classified as private (n=1 individual), populationspecific (n>1 individual in a group), widespread (n>1 individual in more than one group) or 682 shared (n>1 individual in all four groups). Around ~ 29.2% of the total variants across all the 683 four groups were found in just a single individual or population (population-specific), while 684 685 39.7% variants were shared by all the four populations.



686

**Fig. 4: Significant known deleterious and known potentially deleterious variants across groups.** The known variants categorized in the (a) deleterious and (b) potentially deleterious types across groups were assessed for the significance of the allele frequencies in comparison to those reported in 1000 Genome phase 3 dataset (left panel) and the GenomeAsia 100k dataset (right panel). Significance was determined using Fisher's exact test followed by BH-correction for accuracy. The ones not reported in either of the datasets are omitted.



694

# 695 Fig. 5: Genetic diversity and type of drug-metabolism for the PharmGKB VIP genes across

**groups.** (a) and (b) focus on a few CYP450 genes, where they represent the allele frequency and

697 the proportion of different types of metabolizers corresponding to the genotype of the individual, 698 respectively. Similarly, (c) and (d) are for the non-cytochrome P450 genes. The diploid genotype

699 of an individual determines the activity levels of the drug metabolizer protein.

# Proportion of inbred and outbred individuals in the groups

Group	Total samples	Outbred (%)	Inbred (%)				
			1C	2C	1X2C		
Kalinga	73	43.8	13.7	31.5	11		
Kallar	72	12.5	11.1	69.4	6.9		
Reddy	50	44	6	18	32		
Yadav	86	61.6	17.4	15.8	5.8		

	ROH st	atistics across	s groups	
Population	Mean ROH number per individual	SD	Mean ROH length per inidivual	SD
Kalinga	7.79	9.6	3.71	1.83
Kallar	8.86	8.15	6.23	2.84
Reddy	8.6	6.67	6.06	2.45
Yadav	6.52	9.39	4.12	3.74

Position	Gene	REF	ALT	AltHetCount	AltHomCount	RefHomCount	Consequence type	Population	Gene Function	Associated Disorders	ΔΔG
chr1:223762229	CAPN2	Т	С	9	0	64	missesnse variant	Kalinga	calcium-activated intracellular cysteine proteases, are nonlysosomal	lethality, muscular dystrophies, gastropathy (IBD) and diabetes	-2.23
chr3:157159829	CCNL1	А	G	7	0	65	missense variant	Kalinga	cyclin-dependent protein serine/threonine kinase regulation of transcription by RNA polymerase II	Neuropathies, Tarsal Tunnel Syndrome	-0.94
chr20:47663089	SULF2	А	С	6	0	67	missense variant	Kalinga	Exhibits arylsulfatase activity and highly specific endoglucosamine-6-sulfatase activity	Loss of arylsulfatase activity	-1.91
chr2:71077557	NAGK	G	Т	4	0	69	splice_acceptor_variant,N MD_transcript_variant	Kalinga	encodes a member of the N-acetylhexosamine kinase family. Catalyzes the conversion of N- acetyl-D-glucosamine to N-acetyl-D-glucosamine 6-phosphate, and is the major mammalian enzyme which recovers amino sugars.	Nonaka myopathy, Sialuria	
chr2:219541663	CHPF	G	Т	4	0	69	missense variant	Kalinga	Involved in chondroitin sulfate biosynthetic process.	Spondyloepimetaphyseal Dysplasia with congenital Joint Dislocations	-2.03
chr8:67093541	CSPP1	А	G	4	0	69	splice_acceptor_variant,N MD_transcript_variant	Kalinga	cell-cycle-dependent microtubule organization.	Joubert Syndrome, Meckel Syndrome 1	
chr14:95535366	GLRX5	G	Т	3	0	70	missense variant	Kalinga	Monothiol glutaredoxin involved in mitochondrial iron-sulfur (Fe/S) cluster transfer	Sideroblastic Anemia, Spasticity with childhood onset	-0.47
chr2:3519367	ADI1	С	A	3	0	69	splice_donor_variant	Kallar	encodes an enzyme that belongs to the aci- reductone dioxygenase family of metal-binding enzymes, which are involved in methionine salvage.	Charcot-Marie-Tooth Disease, Lebe Optic Atrophy and Dystonia	
chr2:9990727	GRHL1	G	А	3	0	69	missense variant	Kallar	Transcription factor involved in epithelial development.	Deafness, Autosomal dominant; Maxillary/Jaw cancer	-1.42
chr4:8080688	ABLIM2	Т	С	3	0	69	missense variant	Kallar	Predicted to enable actin filament binding activity.		-0.65
chr15:75607298	SNUPN	Т	С	3	0	69	missense variant	Kallar	Involved in the trimethylguanosine (m3G)-cap- dependent nuclear import of U snRNPs. No paralogs		-3.23
chr20:45843560	ACOT8	А	G	4	0	46	missense variant	Reddy	Catalyzes the hydrolysis of acyl-CoAs into free fatty acids and coenzyme A .	Non-syndromic X-linked Intellectual Disability, Hypotrichosis 1, Zellweger syndrome	1.05
chr6:53795353	LRRC1	С	Т	3	0	47	missense variant	Reddy		Intellectual developmental disorder with short stature and behavioural abnormalities, epilepsy	-1.37

Page 1

chr17:4952890	ENO3	G	А	3	0	47	missense_variant,splice_r egion_variant	Reddy	Glycolytic enzyme catalyzing conversion of 2- phosphoglycerate to phosphoenolpyruvate. Functions in striated muscle development and regeneration.	-1.47
chr1:1926894	CFAP74	С	G	2	0	48	missense_variant,splice_r egion_variant	Reddy	As part of the central apparatus of the cilium axoneme may play a role in cilium movement. Ciliary Dyskinesis, May play an important role in sperm architecture Primary, 49 and function.	-1.41
chr1:19327226	SLC66A1	G	Т	2	0	48	splice_acceptor_variant,N MD_transcript_variant	Reddy	Amino acid transporter that specifically mediates       Gallbladder Papillomatosis,         the pH-dependent export of the cationic amino       Fanconi Syndrome,         acids from lysosomes.       Cystinosis	
chr2:232523058	PRSS56	А	G	2	0	48	splice_acceptor_variant	Reddy	Serine protease required during eye development. Microphthalmia, Isolated	
chr3:50348764	NPRL2	С	Т	2	0	48	missense variant	Reddy	Part of GATOR1 complex, a multiprotein complex Epilepsy, Familial Focal; that functions as an inhibitor of the amino acid- sensing branch of the mTORC1 pathway. Distress Syndrome	-1.16
chr11:62790834	TMEM223	А	С	2	0	48	missense variant	Reddy	Mitochondrial ribosome-associated protein involved in the first steps of cytochrome c oxidase complex (complex IV) biogenesis Bisability	-4.84
chr19:38601443	MAP4K1	Т	А	2	0	48	missense variant	Reddy	Serine/threonine-protein kinase, which may play a role in the response to environmental stress Melnick-Needles Syndrome	0.02
chr12:52489942	KRT6A	С	Т	4	0	82	splice_donor_variant	Yadav	Epidermis-specific type I keratin involved in wound healing. Involved in the activation of follicular keratinocytes after wounding	
chr17:27301871	WSB1	Т	G	4	0	82	missense variant	Yadav	Probable substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.	-2.25
chr19:40780052	RAB4B	С	Т	4	0	82	missense variant	Yadav	Small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state (By similarity). Protein transport. Probably involved in vesicular traffic	-0.28

Risk allele	Gene		No. of risk alleles in the genotyped individuals (%)					
ivisk dilete	Gene	rnenotype	Kalinga	Kallar	Reddy	uudis ( /0) Vehev		
rs1051266	SI C19A1	Arthritis Rheumatoid	69.18	70 1 <i>4</i>	53	59.3		
rs1801133	MTHER	Arthritis, Rheumatoid	8.22	8 33	7	11.05		
rs3918290		PM	0.22	0.55	, 3	11.05		
rs1801160		Neoplasms	_ 1 79	_ 15.97	7	6.4		
rs1801265		Neoplasms	17 12	27.78	7	0.4 27 91		
rs56038477		Neoplasms	17.12	27.70	_	27.31		
rs2297595		Neoplasms	6.85	4 17	11.46	13 37		
rs1801159		Neoplasms	6.16	9.72	11.40	8 14		
rs2108622	CVP/F2	Increased warfarin dose requirement	46 58	/5.83	_	50 58		
rs22100022	ABCG2	Rosuvastatin toxicity	17.81	12.5	10.2	7 56		
rs116855232	NUDT15	dosage: IBD myelosupresion	2 74	11.81	10.2	9.88		
rs22/2/20		nain nostoperative	2.74 /1 78	11.01	_	5.00		
rs2745274	CVD2B6	HIV infoctions	41.70	34.03	_	28.05		
rs/1/0056	SI CO1B1	Statin related myonathy	23.30 1 79	5 56	_	4.65		
rc0072721	VKOPC1	Higher warfarin consitivity	4.79	5.50	-	4.05		
155525251	VKOKCI	Thrombosic	_	-	-	_		
150025 CVD2DC*C	F5 CVD2DC	Degrapped function	_ DF 04	2.00	_	-		
CYP2DC*0	CYP2B0	Decreased function	25.34	22.22	-	27.04		
CYP2B0*9	CYP2B0		1.37	4.17	-	1./		
CYP2B6*4	CYP2B6	Increased function	6.16	10.42	18	2.84		
CYP2C9*3	CYP2C9	No function	2.74	16.67	6	13.64		
CYP2C9*2	CYP2C9	Decreased function	6.16	2.78	-	2.27		
CYP2C19*3	CYP2C19	No function	2.74	11.11	_	15.34		
CYP2C19*2	CYP2C19	No function	26.71	_	-	_		
CYP2C19*17	CYP2C19	Increased function	23.29	_	_	-		
CYP2D6*3	CYP2D6	No function	13.7	2.08	3	20.45		
CYP2D6*4	CYP2D6	No function	23.29	20.83	25	5.11		
CYP2D6*41	CYP2D6	Decreased function	13.7	13.19	10	12.5		
CYP3A5*3	CYP3A5	No function	42.47	_	_			
NUDT15*3	NUDT15	No function	2.74	11.11	_	9.09		
UGT1A1*6	UGT1A1	Decreased function, PM	2.05	_	6			
HLA-B*15:02	HLA-B	Increased risk of SCAR	4.79	2.08	1	1.7		
HLA-B*57:01	HLA-B	Increased risk of SCAR	11.64	9.72	3	9.66		
HLA-B*58:01	HLA-B	Increased risk of SCAR	4.11	1.39	3	1.7		

Details of VIP gene variants from PharmGKB across groups

		List of E	ERAP1 allotyp	es in the AS-po	sitive sample	S				
	Amino acid composition at each SNP									
Sample	rs3734016 (E56K)	rs26653 (R127P)	rs26618 (I276M)	rs2287987 (M349V)	rs30187 (K528R)	rs10050860 (D575N)	rs17482078 (R725Q)	rs27044 (Q730E)		
AS1	E	Р	I	V	К	Ν	Q	E		
AS2	E	Р	М	М	К	D	R	E		
AS3	E	Р	I	V	К	Ν	Q	E		
AS4	E	Р	I	М	К	D	R	E		
AS5	E	R	I	М	К	D	R	E		
AS6	E	Р	I	М	К	D	R	E		
AS7	E	Р	М	Μ	К	D	R	E		

\*AS – Ankylosing Spondylitis , 1 -7 are the 7 positive samples